CloneID: 1C10
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated by immunizing a rat with 20 µg of soluble extracellular domain of recombinant murine CD40 (sCD40).
Buffer Composition: PBS with 0.02% Proclin 300.
Chimeric Use Statement: This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG2a format for improved compatibility with existing reagents assays and techniques.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P27512
Specificity Statement: This antibody binds mouse CD40, which is a member of the tumor necrosis factor receptor superfamily. CD40 is an integral membrane protein found on the surface of B lymphocytes.
Application Notes (Clone): This antibody was reported to directly induce a specific proliferative response from mature murine B cells, up-regulate several B cell surface antigens, and rescue immature B lymphoma cells from anti-IgM-induced growth arrest. This initial screening of hybridoma supernatants for reactivity towards CD40 transfected L cells was done using flow cytometry. This antibody recognized recombinant CD40 expressed on L cells and the soluble extracellular domain of murine CD40 coated onto microtiter plates in an ELISA. This antibody was also used in the immunofluorescent staining of adult murine spleen cells. The staining was restricted to the B220+ population. This antibody also specifically immunoprecipitated a 45-kDa protein from the surface of purified murine splenic B cells (PMID: 7519997). This antibody was capable of blocking binding of FGK45 to CD40 on murine B cells in vitro (PMID: 24416732). The mouse IgG1 version of this antibody had a tenfold higher affinity for mouse FcγRIIB as compared to mouse IgG2a or the parental rat IgG2b (PMID: 21852502). The mouse IgG1 version of this antibody was used in the treatment of M38 tumor bearing mice and it was reported that there was a strong increase in PD-L1 expression both on tumor-infiltrating monocytes and TAMs (PMID: 25623164).
Deutsch
English
